Google DeepMind, Meta: Isomorphic Labs invests $300 million in Biohub initiative to build AI data for disease treatment
deepmind drug-discovery google meta
| Source: Yahoo Finance | Original article
Google DeepMind, Meta and Isomorphic Labs are contributing $300 million to Biohub’s Virtual Biology Initiative, bolstering the $1.8 billion effort to create AI datasets for disease treatment.
Google DeepMind, Meta and Isomorphic Labs have pledged a combined $300 million to the Chan Zuckerberg Biohub’s Virtual Biology Initiative, announced on 7 October 2026. The funding will accelerate the creation of large‑scale, high‑fidelity datasets that train AI models to predict cellular responses and, ultimately, to simulate virtual cells for drug discovery. The investment is part of a broader $1.8 billion effort that also includes matching contributions from the U.S. Department of Energy and the National Institutes of Health, as well as over $1 billion in computational and measurement infrastructure.
The move marks the deepest joint commitment yet from leading tech firms to the nascent field of AI‑driven biology. By supplying the data needed for “virtual cell” models, the partners aim to shorten the experimental cycle, reduce reliance on costly wet‑lab work, and open new pathways for precision therapeutics. The initiative builds on the $1.8 billion global commitment to AI‑ready biological data we reported earlier this month, underscoring a rapid consolidation of public and private resources around computational biology.
Biohub’s head of science says the first curated dataset should be available within roughly a year, giving researchers early access to a standardized foundation for model training. Meanwhile, other AI players such as Anthropic and OpenAI are also pursuing biology‑focused data pipelines, suggesting a competitive landscape that could spur further investment and innovation.
What to watch next: the rollout of the initial dataset and the first benchmark results from AI models trained on it; additional funding rounds or partnerships announced by the DOE, NIH, or other industry players; and any early indications of drug candidates emerging from the virtual cell platform. These milestones will reveal how quickly AI can move from data generation to tangible therapeutic outcomes.
Sources
Back to AIPULSEN